Rapid point of care tests to detect COVID-19

Rapid point of care tests to determine infection (Antigen-tests) and/or past infection and/or vaccination (Antibody-tests) are urgently needed in the current COVID-19 pandemic. Ingenasa is a company that has the expertise on board to make the tests. Combined with the unique coronavirus cultures and human monoclonal antibody expertise at the Amsterdam UMC there is a public-private partnership that combines knowledge and materials. The partnership managed to develop highly sensitive and specific antibody tests based on the novel Dual Recognition principle.